All Stories

  1. Ultra-processed foods and type 2 diabetes: more fundamental research is needed

    Article • The Lancet Regional Health - Europe, November 2024, Elsevier

    JAMJL Janssen

  2. Overnutrition, Hyperinsulinemia and Ectopic Fat: It Is Time for A Paradigm Shift in the Management of Type 2 Diabetes

    Article • International Journal of Molecular Sciences, May 2024, MDPI AG

    JAMJL Janssen

  3. The Impact of Westernization on the Insulin/IGF-I Signaling Pathway and the Metabolic Syndrome: It Is Time for Change

    Article • International Journal of Molecular Sciences, February 2023, MDPI AG

    JAMJL Janssen

  4. New Insights into the Role of Insulin and Hypothalamic-Pituitary-Adrenal (HPA) Axis in the Metabolic Syndrome

    Article • International Journal of Molecular Sciences, July 2022, MDPI AG

    JAMJL Janssen

  5. It Takes Two to Tango: IGF-I and TSH Receptors in Thyroid Eye Disease

    Article • The Journal of Clinical Endocrinology & Metabolism, February 2022, Endocrine Society

    JAMJL Janssen

  6. Hyperinsulinemia and Its Pivotal Role in Aging, Obesity, Type 2 Diabetes, Cardiovascular Disease and Cancer

    Article • International Journal of Molecular Sciences, July 2021, MDPI AG

    JAMJL Janssen

  7. Modifying Effects of Glucose and Insulin/Insulin-Like Growth Factors on Colon Cancer Cells

    Article • Frontiers in Oncology, July 2021, Frontiers

    JAMJL Janssen

  8. Lessons Learned from Targeting IGF-I Receptor in Thyroid-Associated Ophthalmopathy

    Article • Cells, February 2021, MDPI AG

    JAMJL Janssen

  9. Mechanisms of putative IGF-I receptor resistance in active acromegaly

    Article • Growth Hormone & IGF Research, June 2020, Elsevier

    JAMJL Janssen

  10. Soluble Klotho: a possible predictor of quality of life in acromegaly patients

    Article • Endocrine, April 2020, Springer Science + Business Media

    JAMJL Janssen

  11. New Insights from IGF-IR Stimulating Activity Analyses: Pathological Considerations

    Article • Cells, April 2020, MDPI AG

    JAMJL Janssen

  12. Fractures, Bone Mineral Density, and Final Height in Craniopharyngioma Patients with a Follow-up of 16 Years

    Article • The Journal of Clinical Endocrinology & Metabolism, March 2020, Endocrine Society

    JAMJL Janssen

  13. The insulin-like growth factor-I receptor stimulating activity (IRSA) in health and disease

    Article • Growth Hormone & IGF Research, October 2019, Elsevier

    JAMJL Janssen

  14. Diagnosing metabolic syndrome in craniopharyngioma patients: body composition versus BMI

    Article • European Journal of Endocrinology, August 2019, Bioscientifica

    JAMJL Janssen

  15. IGF and mTOR pathway expression and in vitro effects of linsitinib and mTOR inhibitors in adrenocortical cancer

    Article • Endocrine, March 2019, Springer Science + Business Media

    JAMJL Janssen

  16. IGF-I and the endocrinology of aging

    Article • Current Opinion in Endocrine and Metabolic Research, March 2019, Elsevier

    JAMJL Janssen

  17. Revisiting the Role of Insulin-Like Growth Factor-I Receptor Stimulating Activity and the Apolipoprotein E in Alzheimer’s Disease

    Article • Frontiers in Aging Neuroscience, February 2019, Frontiers

    JAMJL Janssen

  18. How to Position Pasireotide LAR Treatment in Acromegaly

    Article • The Journal of Clinical Endocrinology & Metabolism, January 2019, Endocrine Society

    JAMJL Janssen

  19. Efficacy and safety of switching to pasireotide in acromegaly patients controlled with pegvisomant and somatostatin analogues: PAPE extension study

    Article • European Journal of Endocrinology, November 2018, Bioscientifica

    JAMJL Janssen

  20. Pasireotide Responsiveness in Acromegaly Is Mainly Driven by Somatostatin Receptor Subtype 2 Expression

    Article • The Journal of Clinical Endocrinology & Metabolism, October 2018, Endocrine Society

    JAMJL Janssen

  21. Insulin-like Growth Factor-I Receptor and Thyroid-Associated Ophthalmopathy

    Article • Endocrine Reviews, September 2018, Endocrine Society

    JAMJL Janssen

  22. Improved Glucose Tolerance in a Kidney Transplant Recipient With Type 2 Diabetes Mellitus After Switching From Tacrolimus To Belatacept: A Case Report and Review of Potential Mechanisms

    Article • Transplantation Direct, March 2018, Wolters Kluwer Health

    JAMJL Janssen

  23. Genetic influence on the associations between IGF-I and glucose metabolism in a cohort of elderly twins

    Article • European Journal of Endocrinology, December 2017, Bioscientifica

    JAMJL Janssen

  24. Efficacy and safety of switching to pasireotide in acromegaly patients controlled with pegvisomant and first-generation somatostatin analogues (PAPE study)

    Article • The Journal of Clinical Endocrinology & Metabolism, November 2017, Endocrine Society

    JAMJL Janssen

  25. Response to Krieger et al. re: “TSHR/IGF-1R Cross-Talk, Not IGF-1R Stimulating Antibodies, Mediates Graves' Ophthalmopathy Pathogenesis” (Thyroid 2017;27:746–747)

    Article • Thyroid, November 2017, Mary Ann Liebert Inc

    JAMJL Janssen

  26. Disagreement in normative insulin-like growth factor-I levels in growth hormone deficiency

    Article • Clinical Endocrinology, October 2017, Wiley

    JAMJL Janssen

  27. Excess morbidity and mortality in patients with craniopharyngioma: a hospital-based retrospective cohort study

    Article • European Journal of Endocrinology, October 2017, Bioscientifica

    Mr Mark Wijnen, JAMJL Janssen, Professor Gudmundur Johannsson

  28. The metabolic syndrome and its components in 178 patients treated for craniopharyngioma after 16 years of follow-up

    Article • European Journal of Endocrinology, September 2017, Bioscientifica

    Mr Mark Wijnen, JAMJL Janssen, Professor Gudmundur Johannsson

  29. Serum Insulin Bioassay Reflects Insulin Sensitivity and Requirements in Type 1 Diabetes

    Article • The Journal of Clinical Endocrinology & Metabolism, August 2017, Endocrine Society

    JAMJL Janssen, Sonia Fernandez-Veledo

  30. Very long-term sequelae of craniopharyngioma

    Article • European Journal of Endocrinology, March 2017, Bioscientifica

    Mr Mark Wijnen, JAMJL Janssen

  31. Building the Case for Insulin-Like Growth Factor Receptor-I Involvement in Thyroid-Associated Ophthalmopathy

    Article • Frontiers in Endocrinology, January 2017, Frontiers

    JAMJL Janssen

  32. Efficacy and safety of bariatric surgery for craniopharyngioma-related hypothalamic obesity: a matched case–control study with 2 years of follow-up

    Article • International Journal of Obesity, October 2016, Nature

    Mr Mark Wijnen, JAMJL Janssen, Professor Gudmundur Johannsson

  33. Methylation ofIGF2regulatory regions to diagnose adrenocortical carcinomas

    Article • Endocrine Related Cancer, August 2016, Bioscientifica

    JAMJL Janssen

  34. Somatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with Pegvisomant

    Article • Neuroendocrinology, July 2016, Karger Publishers

    JAMJL Janssen

  35. Genomewide meta‐analysis identifies loci associated with IGF ‐I and IGFBP ‐3 levels with impact on age‐related traits

    Article • Aging Cell, June 2016, Wiley

    JAMJL Janssen

  36. Potency of Full- Length MGF to Induce Maximal Activation of the IGF-I R Is Similar to Recombinant Human IGF-I at High Equimolar Concentrations

    Article • PLoS ONE, March 2016, PLOS

    JAMJL Janssen

  37. A Meta-analysis of Individual Participant Data Reveals an Association between Circulating Levels of IGF-I and Prostate Cancer Risk

    Article • Cancer Research, February 2016, American Association for Cancer Research (AACR)

    JAMJL Janssen

  38. What is the efficacy of switching to weekly pegvisomant in acromegaly patients well controlled on combination therapy?

    Article • European Journal of Endocrinology, February 2016, Bioscientifica

    JAMJL Janssen

  39. Effects of Somatostatin Analogs and Dopamine Agonists on Insulin-Like Growth Factor 2-Induced Insulin Receptor Isoform A Activation by Gastroenteropancreatic Neuroendocrine Tumor Cells

    Article • Neuroendocrinology, January 2016, Karger Publishers

    Prof Wouter WW de Herder, JAMJL Janssen

  40. Impact of Physical Exercise on Endocrine Aging

    Article • January 2016, Karger Publishers

    JAMJL Janssen

  41. Correction: An Early Diagnostic Tool for Diabetic Peripheral Neuropathy in Rats

    Article • PLoS ONE, June 2015, PLOS

    JAMJL Janssen

  42. Absence or low IGF-1R-expression in esophageal adenocarcinoma is associated with tumor invasiveness and radicality of surgical resection

    Article • Journal of Surgical Oncology, June 2015, Wiley

    JAMJL Janssen

  43. An Early Diagnostic Tool for Diabetic Peripheral Neuropathy in Rats

    Article • PLoS ONE, May 2015, PLOS

    JAMJL Janssen

  44. Changes in circulating IGF1 receptor stimulating activity do not parallel changes in total IGF1 during GH treatment of GH-deficient adults

    Article • May 2015, Bioscientifica

    JAMJL Janssen

  45. The Introduction of the IDS-iSYS Total IGF-1 Assay May Have Far-Reaching Consequences for Diagnosis and Treatment of GH Deficiency

    Article • The Journal of Clinical Endocrinology & Metabolism, January 2015, Endocrine Society

    JAMJL Janssen

  46. IGF-IR Targeted Therapy: Past, Present and Future

    Article • Frontiers in Endocrinology, December 2014, Frontiers

    JAMJL Janssen

  47. Long-Term Efficacy and Safety of Pegvisomant in Combination With Long-Acting Somatostatin Analogs in Acromegaly

    Article • The Journal of Clinical Endocrinology & Metabolism, October 2014, Endocrine Society

    JAMJL Janssen

  48. Insulin-Like Growth Factor-I Receptor Stimulating Activity is Associated with Dementia

    Article • Journal of Alzheimer’s Disease, August 2014, IOS Press

    JAMJL Janssen

  49. Characterization of the mTOR pathway in human normal adrenal and adrenocortical tumors

    Article • June 2014, Bioscientifica

    JAMJL Janssen

  50. Insulin Analogs and Cancer: A Note of Caution

    Article • Frontiers in Endocrinology, May 2014, Frontiers

    JAMJL Janssen

  51. Expression of IGF/mTOR pathway components in human pheochromocytomas and in vitro inhibition of PC12 rat pheochromocytoma cell growth by mTOR inhibitors alone and in combination with the dual IGFI-R/INS-R antagonist OSI-906

    Article • April 2014

    JAMJL Janssen

  52. In active acromegaly, IGF1 bioactivity is related to soluble Klotho levels and quality of life

    Article • April 2014, Bioscientifica

    JAMJL Janssen

  53. Diabetes Associated with Glucocorticoid Excess

    Article • January 2014, Karger Publishers

    JAMJL Janssen

  54. The IGSF1 Deficiency Syndrome: Characteristics of Male and Female Patients

    Article • The Journal of Clinical Endocrinology & Metabolism, December 2013, Endocrine Society

    JAMJL Janssen

  55. Chromogranin A, Ki-67 index and IGF-related genes in patients with neuroendocrine tumors

    Article • September 2013, Bioscientifica

    JAMJL Janssen, Prof Wouter WW de Herder

  56. Concentrations of Insulin Glargine and Its Metabolites During Long-Term Insulin Therapy in Type 2 Diabetic Patients and Comparison of Effects of Insulin Glargine, Its Metabolites, IGF-I, and Human Insulin on Insulin and IGF-I Receptor Signaling

    Article • Diabetes, June 2013, American Diabetes Association

    JAMJL Janssen

  57. P-0045 * THE ROLE OF THE NOVEL SELECTIVE DUAL INHIBITOR OF THE IGF-IR/IR ON PROLIFERATION AND MIGRATION OF HUMAN PANCREATIC CANCER CELLS

    Article • Annals of Oncology, June 2013, Oxford University Press (OUP)

    JAMJL Janssen

  58. Hormone Replacement Therapy

    Article • March 2013, Wiley

    JAMJL Janssen

  59. IGF-I Bioactivity Might Reflect Different Aspects of Quality of Life Than Total IGF-I in GH-Deficient Patients During GH Treatment

    Article • The Journal of Clinical Endocrinology & Metabolism, February 2013, Endocrine Society

    JAMJL Janssen

  60. Circulating IgGs May Modulate IGF-I Receptor Stimulating Activity in a Subset of Patients With Graves' Ophthalmopathy

    Article • The Journal of Clinical Endocrinology & Metabolism, February 2013, Endocrine Society

    JAMJL Janssen

  61. High Bone Mineral Density and Fracture Risk in Type 2 Diabetes as Skeletal Complications of Inadequate Glucose Control: The Rotterdam Study

    Article • Diabetes Care, January 2013, American Diabetes Association

    JAMJL Janssen

  62. Circulating insulin-like growth factors may contribute substantially to insulin receptor isoform A and insulin receptor isoform B signalling

    Article • Molecular and Cellular Endocrinology, January 2013, Elsevier

    JAMJL Janssen

  63. High IGFBP2 levels are not only associated with a better metabolic risk profile but also with increased mortality in elderly men

    Article • May 2012, Bioscientifica

    JAMJL Janssen

  64. Insulin and its analogues and their affinities for the IGF1 receptor

    Article • March 2012, Bioscientifica

    JAMJL Janssen

  65. Addition of insulin glargine or NPH insulin to metformin monotherapy in poorly controlled type 2 diabetic patients decreases IGF-I bioactivity similarly

    Article • Diabetologia, January 2012, Springer Science + Business Media

    JAMJL Janssen

  66. Effect of Intensive Insulin Therapy on the Somatotropic Axis of Critically Ill Children

    Article • The Journal of Clinical Endocrinology & Metabolism, August 2011, Endocrine Society

    JAMJL Janssen

  67. IGF-I Bioactivity Better Reflects Growth Hormone Deficiency than Total IGF-I

    Article • The Journal of Clinical Endocrinology & Metabolism, July 2011, Endocrine Society

    JAMJL Janssen

  68. Pasireotide Treatment in Cushing Disease: Effects on the IGF-I System

    Article • June 2011, Endocrine Society

    JAMJL Janssen

  69. IGF-I Bioactivity More Accurately Reflects Growth Hormone Deficiency Than Total-IGF-I

    Article • June 2011, Endocrine Society

    JAMJL Janssen

  70. IGF-I Bioactivity Decreases during Insulin Therapy in Type 2 Diabetic Patients: Comparison of High Doses of Insulin Glargine and NPH Insulin in the LANMET Study

    Article • June 2011, Endocrine Society

    JAMJL Janssen

  71. Insulin-Like Growth Factor I: Pros and Cons of a Bioassay

    Article • Hormone Research in Paediatrics, January 2011, Karger Publishers

    JAMJL Janssen

  72. Insulin glargine is more potent in activating the human IGF-I receptor than human insulin and insulin detemir

    Article • Growth Hormone & IGF Research, December 2010, Elsevier

    JAMJL Janssen

  73. Novel Specific Kinase Receptor Activation Bioassays for the Human Insulin Receptor A (IR-A) and B (IR-B) To Study the Insulin-IGF System.

    Article • June 2010, Endocrine Society

    JAMJL Janssen

  74. IGF-I Bioactivity in an Elderly Population

    Article • Diabetes, February 2010, American Diabetes Association

    JAMJL Janssen

  75. P108 Effect of intensive insulin therapy on the somatotropic axis in critically ill children

    Article • Growth Hormone & IGF Research, January 2010, Elsevier

    JAMJL Janssen

  76. Bioactive rather than total IGF-I is involved in acute responses to nutritional interventions in CAPD patients

    Article • Nephrology Dialysis Transplantation, November 2009, Oxford University Press (OUP)

    JAMJL Janssen

  77. Heterophilic antibodies may be a cause of falsely low total IGF1 levels

    Article • European Journal of Endocrinology, October 2009, Bioscientifica

    JAMJL Janssen

  78. Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients

    Article • European Journal of Endocrinology, April 2009, Bioscientifica

    JAMJL Janssen

  79. Effects of type I interferons on IGF-mediated autocrine/paracrine growth of human neuroendocrine tumor cells

    Article • AJP Endocrinology and Metabolism, December 2008, American Physiological Society

    JAMJL Janssen

  80. Quality of Life in Acromegalic Patients during Long-Term Somatostatin Analog Treatment with and without Pegvisomant

    Article • The Journal of Clinical Endocrinology & Metabolism, October 2008, Endocrine Society

    JAMJL Janssen

  81. Advantages and disadvantages of GH/IGF-I combination treatment

    Article • Reviews in Endocrine and Metabolic Disorders, July 2008, Springer Science + Business Media

    JAMJL Janssen

  82. Normal Values of Circulating Insulin-Like Growth Factor-I Bioactivity in the Healthy Population: Comparison with Five Widely Used IGF-I Immunoassays

    Article • The Journal of Clinical Endocrinology & Metabolism, July 2008, Endocrine Society

    JAMJL Janssen

  83. Low Circulating Insulin-Like Growth Factor I Bioactivity in Elderly Men Is Associated with Increased Mortality

    Article • The Journal of Clinical Endocrinology & Metabolism, July 2008, Endocrine Society

    JAMJL Janssen

  84. Long-Term Efficacy and Safety of Combined Treatment of Somatostatin Analogs and Pegvisomant in Acromegaly

    Article • The Journal of Clinical Endocrinology & Metabolism, December 2007, Endocrine Society

    JAMJL Janssen

  85. Intravenous Glucose Administration in Fasting Rats Has Differential Effects on Acylated and Unacylated Ghrelin in the Portal and Systemic Circulation: A Comparison between Portal and Peripheral Concentrations in Anesthetized Rats

    Article • Endocrinology, November 2007, Endocrine Society

    JAMJL Janssen

  86. Unacylated ghrelin acts as a potent insulin secretagogue in glucose-stimulated conditions

    Article • AJP Endocrinology and Metabolism, September 2007, American Physiological Society

    JAMJL Janssen

  87. IGF-1 CA repeat variant and breast cancer risk in postmenopausal women

    Article • European Journal of Cancer, July 2007, Elsevier

    JAMJL Janssen

  88. The Asp727Glu polymorphism in the TSH receptor is associated with insulin resistance in healthy elderly men

    Article • Clinical Endocrinology, June 2007, Wiley

    JAMJL Janssen

  89. Effects of the Renin-Angiotensin System Genes and Salt Sensitivity Genes on Blood Pressure and Atherosclerosis in the Total Population and Patients With Type 2 Diabetes

    Article • Diabetes, April 2007, American Diabetes Association

    JAMJL Janssen

  90. An IGF-I gene polymorphism modifies the risk of developing persistent microalbuminuria in type 1 diabetes

    Article • January 2007

    JAMJL Janssen

  91. IGF-I gene promoter polymorphism is a predictor of survival after myocardial infarction in patients with type 2 diabetes

    Article • November 2006

    JAMJL Janssen

  92. The  -Adducin Gene Is Associated With Macrovascular Complications and Mortality in Patients With Type 2 Diabetes

    Article • Diabetes, September 2006, American Diabetes Association

    JAMJL Janssen

  93. An IGF-I Gene Polymorphism Modifies the Risk of Diabetic Retinopathy

    Article • Diabetes, August 2006, American Diabetes Association

    JAMJL Janssen

  94. Short-term administration of an angiotensin-receptor antagonist in patients with impaired fasting glucose improves insulin sensitivity and increases free IGF-I

    Article • European Journal of Endocrinology, August 2006, Bioscientifica

    JAMJL Janssen

  95. Unacylated ghrelin is active on the INS-1E rat insulinoma cell line independently of the growth hormone secretagogue receptor type 1a and the corticotropin releasing factor 2 receptor

    Article • Molecular and Cellular Endocrinology, June 2006, Elsevier

    JAMJL Janssen

  96. An Insulin-Like Growth Factor-I Promoter Polymorphism Is Associated With Increased Mortality in Subjects With Myocardial Infarction in an Elderly Caucasian Population

    Article • The American Journal of Cardiology, May 2006, Elsevier

    JAMJL Janssen

  97. An insulin-like growth factor-I gene polymorphism modifies the risk of microalbuminuria in subjects with an abnormal glucose tolerance

    Article • European Journal of Endocrinology, May 2006, Bioscientifica

    JAMJL Janssen

  98. Retinal Vessel Diameters and Risk of Impaired Fasting Glucose or Diabetes: The Rotterdam Study

    Article • Diabetes, January 2006, American Diabetes Association

    JAMJL Janssen

  99. The IGF‐I system and the renal and haemodynamic effects of losartan in normotensive patients with type 2 diabetes mellitus: a randomized clinical trial

    Article • Clinical Endocrinology, January 2006, Wiley

    JAMJL Janssen

  100. Postoperative Evaluation of Patients with Acromegaly: Clinical Significance and Timing of Oral Glucose Tolerance Testing and Measurement of (Free) Insulin-Like Growth Factor I, Acid-Labile Subunit, and Growth Hormone-Binding Protein Levels

    Article • The Journal of Clinical Endocrinology & Metabolism, December 2005, Endocrine Society

    JAMJL Janssen

  101. A new polymorphism in the type II deiodinase gene is associated with circulating thyroid hormone parameters

    Article • AJP Endocrinology and Metabolism, July 2005, American Physiological Society

    JAMJL Janssen

  102. Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF-I normalization with Sandostatin LAR in acromegaly

    Article • June 2005

    JAMJL Janssen

  103. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly

    Article • The Lancet, May 2005, Elsevier

    JAMJL Janssen

  104. The 'bio-assay' quality of life might be a better marker of disease activity in acromegalic patients than serum total IGF-I concentrations

    Article • February 2005

    JAMJL Janssen

  105. Ghrelin Stimulates, Whereas Des-Octanoyl Ghrelin Inhibits, Glucose Output by Primary Hepatocytes

    Article • The Journal of Clinical Endocrinology & Metabolism, February 2005, Endocrine Society

    JAMJL Janssen

  106. A promoter polymorphism of the insulin-like growth factor-I gene is associated with left ventricular hypertrophy

    Article • Heart, February 2005, BMJ

    JAMJL Janssen

  107. A Polymorphism in Type I Deiodinase Is Associated with Circulating Free Insulin-Like Growth Factor I Levels and Body Composition in Humans

    Article • The Journal of Clinical Endocrinology & Metabolism, January 2005, Endocrine Society

    JAMJL Janssen

  108. Administration of Acylated Ghrelin Reduces Insulin Sensitivity, Whereas the Combination of Acylated Plus Unacylated Ghrelin Strongly Improves Insulin Sensitivity

    Article • The Journal of Clinical Endocrinology & Metabolism, October 2004, Endocrine Society

    JAMJL Janssen

  109. The role of polymorphisms in the IGF-I gene in aging and age-related diseases

    Article • Experimental and Clinical Endocrinology & Diabetes, September 2004, Thieme Publishing Group

    JAMJL Janssen

  110. Circulating Free Insulin-Like Growth Factor (IGF)-I , Total IGF-I, and IGF Binding Protein-3 Levels Do Not Predict the Future Risk to Develop Prostate Cancer: Results of a Case-Control Study Involving 201 Patients within a Population-Based Screening wi...

    Article • The Journal of Clinical Endocrinology & Metabolism, September 2004, Endocrine Society

    JAMJL Janssen

  111. Association of the ER22/23EK polymorphism in the glucocorticoid receptor gene with survival and C-reactive protein levels in elderly men

    Article • The American Journal of Medicine, August 2004, Elsevier

    JAMJL Janssen

  112. Insulin-like growth factor-I gene polymorphism and risk of heart failure (the Rotterdam Study)

    Article • The American Journal of Cardiology, August 2004, Elsevier

    JAMJL Janssen

  113. A polymorphic CA repeat in the IGF‐I gene is associated with gender‐specific differences in body height, but has no effect on the secular trend in body height

    Article • Clinical Endocrinology, July 2004, Wiley

    JAMJL Janssen

  114. The Influence of an Insulin-Like Growth Factor I Gene Promoter Polymorphism on Hip Bone Geometry and the Risk of Nonvertebral Fracture in the Elderly: The Rotterdam Study

    Article • Journal of Bone and Mineral Research, April 2004, Wiley

    JAMJL Janssen

  115. IGF-I and Longevity

    Article • Hormone Research in Paediatrics, January 2004, Karger Publishers

    JAMJL Janssen

  116. IGF-1 Gene Polymorphisms and Disease in the Elderly

    Article • January 2004, Springer Science + Business Media

    JAMJL Janssen

  117. Identification of the BclI polymorphism in the glucocorticoid receptor gene: association with sensitivity to glucocorticoids in vivo and body mass index

    Article • Clinical Endocrinology, November 2003, Wiley

    JAMJL Janssen

  118. Polymorphism in the Promoter Region of the Insulin-like Growth Factor I Gene Is Related to Carotid Intima-Media Thickness and Aortic Pulse Wave Velocity in Subjects With Hypertension

    Article • Stroke, July 2003, Wolters Kluwer Health

    JAMJL Janssen

  119. Circulating free insulin-like growth-factor-I (IGF-I) levels should also be measured to estimate the IGF-I bioactivity

    Article • Journal of Endocrinological Investigation, June 2003, Springer Science + Business Media

    JAMJL Janssen

  120. A polymorphism in the IGF-I gene influences the age-related decline in circulating total IGF-I levels

    Article • February 2003

    JAMJL Janssen

  121. Endogenous Hormones and Carotid Atherosclerosis in Elderly Men

    Article • American Journal of Epidemiology, January 2003, Oxford University Press (OUP)

    JAMJL Janssen

  122. Association entre déficit en IGF-1 et faible poids de naissance

    Article • Revue Fran&c edil aise des Laboratoires, September 2002, Elsevier

    JAMJL Janssen

  123. Acute Stress Response in Children with Meningococcal Sepsis: Important Differences in the Growth Hormone/Insulin-Like Growth Factor I Axis between Nonsurvivors and Survivors

    Article • The Journal of Clinical Endocrinology & Metabolism, July 2002, Endocrine Society

    JAMJL Janssen

  124. Endocrine responses to ghrelin in adult patients with isolated childhood-onset growth hormone deficiency

    Article • Clinical Endocrinology, June 2002, Wiley

    JAMJL Janssen

  125. The role of IGF-I in the development of cardiovascular disease in type 2 diabetes mellitus: is prevention possible?

    Article • April 2002

    JAMJL Janssen

  126. Commentary: A polymorphic CA repeat in the promoter region of the insulin-like growth factor I (IGF-I) gene

    Article • European Journal of Epidemiology, March 2002, Springer Science + Business Media

    JAMJL Janssen

  127. Association between genetic variation in the gene for insulin-like growth factor-l and low birthweight

    Article • The Lancet, March 2002, Elsevier

    JAMJL Janssen

  128. Acute Effect of Pegvisomant on Cardiovascular Risk Markers in Healthy Men: Implications for the Pathogenesis of Atherosclerosis in GH Deficiency

    Article • The Journal of Clinical Endocrinology & Metabolism, November 2001, Endocrine Society

    JAMJL Janssen

  129. Effects of fasting and pegvisomant on the GH-releasing hormone and GH-releasing peptide-6 stimulated growth hormone secretion

    Article • Clinical Endocrinology, October 2001, Wiley

    JAMJL Janssen

  130. A Polymorphism in the Gene for IGF-I

    Article • Diabetes, March 2001, American Diabetes Association

    JAMJL Janssen

  131. Control of Tumor Size and Disease Activity during Cotreatment with Octreotide and the Growth Hormone Receptor Antagonist Pegvisomant in an Acromegalic Patient

    Article • The Journal of Clinical Endocrinology & Metabolism, February 2001, Endocrine Society

    JAMJL Janssen

  132. Blockade of the Growth Hormone (GH) Receptor Unmasks Rapid GH-Releasing Peptide-6-Mediated Tissue-Specific Insulin Resistance

    Article • The Journal of Clinical Endocrinology & Metabolism, February 2001, Endocrine Society

    JAMJL Janssen

  133. Control of Tumor Size and Disease Activity during Cotreatment with Octreotide and the Growth Hormone Receptor Antagonist Pegvisomant in an Acromegalic Patient

    Article • The Journal of Clinical Endocrinology & Metabolism, February 2001, Endocrine Society

    JAMJL Janssen

  134. A Prospective Study on Circulating Insulin-Like Growth Factor I (IGF-I), IGF-Binding Proteins, and Cognitive Function in the Elderly

    Article • The Journal of Clinical Endocrinology & Metabolism, December 2000, Endocrine Society

    JAMJL Janssen

  135. A Prospective Study on Circulating Insulin-Like Growth Factor I (IGF-I), IGF-Binding Proteins, and Cognitive Function in the Elderly

    Article • The Journal of Clinical Endocrinology & Metabolism, December 2000, Endocrine Society

    JAMJL Janssen

  136. Circulating Igf‐I And Its Protective Role In The Pathogenesis Of Diabetic Angiopathy

    Article • Journal of the Peripheral Nervous System, June 2000, Wiley

    JAMJL Janssen

  137. Circulating IGF‐I and its protective role in the pathogenesis of diabetic angiopathy

    Article • Clinical Endocrinology, January 2000, Wiley

    JAMJL Janssen

  138. The GH/IGF-I axis in children with a meningococcal septic shock: striking differences between survivors and non-survivors

    Article • Critical Care, January 2000, Springer Science + Business Media

    JAMJL Janssen

  139. The IGF‐I/IGFBP system in congenital partial lipodystrophy

    Article • Clinical Endocrinology, October 1998, Wiley

    JAMJL Janssen

  140. Insulin-like growth factor-l and risk of breast cancer

    Article • The Lancet, August 1998, Elsevier

    JAMJL Janssen

  141. Insulin-like growth factor-l and risk of breast cancer

    Article • The Lancet, August 1998, Elsevier

    JAMJL Janssen

  142. Lack of associations between serum leptin, a polymorphism in the gene for the beta3-adrenergic receptor and glucose tolerance in the Dutch population.

    Article • Clinical Endocrinology, August 1998, Wiley

    JAMJL Janssen

  143. Gender-specific relationship between serum free and total IGF-I and bone mineral density in elderly men and women

    Article • June 1998

    JAMJL Janssen

  144. The acute effect of dexamethasone on plasma leptin concentrations and the relationships between fasting leptin, the IGF‐I/IGFBP system, dehydroepiandrosterone, androstenedione and testosterone in an elderly population

    Article • Clinical Endocrinology, May 1998, Wiley

    JAMJL Janssen

  145. Serum free IGF‐I, total IGF‐I, IGFBP‐1 and IGFBP‐3 levels in an elderly population: relation to age and sex steroid levels

    Article • Clinical Endocrinology, April 1998, Wiley

    JAMJL Janssen

  146. Adult vs childhood onset GHD: Is there a real clinical difference?

    Article • Growth Hormone & IGF Research, February 1998, Elsevier

    JAMJL Janssen

  147. Insulin-like growth factor I receptors on blood cells: their relationship to circulating total and “free” IGF-I, IGFBP-1, IGFBP-3 and insulin levels in healthy subjects

    Article • Growth Hormone & IGF Research, February 1998, Elsevier

    JAMJL Janssen

  148. Serum Total IGF-I, Free IGF-I, and IGFBP-1 Levels in an Elderly Population

    Article • Arteriosclerosis Thrombosis and Vascular Biology, February 1998, Wolters Kluwer Health

    JAMJL Janssen

  149. Serum Free and Total Insulin-Like Growth Factor-I, Insulin-Like Growth Factor Binding Protein-1 and Insulin-Like Growth Factor Binding Protein-3Levels in Healthy Elderly Individuals

    Article • Gerontology, January 1998, Karger Publishers

    JAMJL Janssen

  150. Free and Total Insulin-Like Growth Factor I (IGF-I), IGF-Binding Protein-1 (IGFBP-1), and IGFBP-3 and Their Relationships to the Presence of Diabetic Retinopathy and Glomerular Hyperfiltration in Insulin-Dependent Diabetes Mellitus

    Article • The Journal of Clinical Endocrinology & Metabolism, September 1997, Endocrine Society

    JAMJL Janssen

  151. Free and Total Insulin-Like Growth Factor I (IGF-I), IGF-Binding Protein-1 (IGFBP-1), and IGFBP-3 and Their Relationships to the Presence of Diabetic Retinopathy and Glomerular Hyperfiltration in Insulin-Dependent Diabetes Mellitus1

    Article • The Journal of Clinical Endocrinology & Metabolism, September 1997, Endocrine Society

    JAMJL Janssen

  152. Study of the molecular mechanism of decreased liver synthesis of albumin in inflammation.

    Article • Journal of Clinical Investigation, June 1987, American Society for Clinical Investigation

    JAMJL Janssen